SPARC's R&D Day highlighted a strategic pivot to focus on oncology and immunology, emphasizing modular platforms and partnerships to reduce clinical risk.

Key programs like SCD-153 (topical for alopecia areata) and SBO-154 (MUC1 ADC for solid tumors) are progressing, with SCD-153's Phase 1B study initiated and SBO-154's Phase 1 dose escalation underway, both ahead of schedule.

Recent developments include a positive court ruling for a valuable Pediatric Rare Diseases Voucher (PRV), potentially exceeding $100 million.

The SCO-155 small-molecule drug conjugate program is also advancing via a NewCo partnership with Tiller Therapeutics.

SPARC achieved significant operational streamlining, cutting annual fixed costs by $10 million and marginally reducing operational spend.

Cumulative promoter-backed debt exceeds $45 million.

Management aims to finalize a funding plan to extend cash runway to FY'28, with early efficacy data for SCD-153 expected by Q4 this year and SBO-154's maximum tolerated dose by Q3 2026. This repositioning aims to unlock future value.